A5082406815- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Radiopharmaceutical Chemistry and Applications
- Glioma Diagnosis and Treatment
- Renal and related cancers
- Mathematical Biology Tumor Growth
- Melanoma and MAPK Pathways
- Cancer Cells and Metastasis
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Neuroendocrine Tumor Research Advances
- Cancer, Lipids, and Metabolism
- Cutaneous Melanoma Detection and Management
- Thyroid Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Bladder and Urothelial Cancer Treatments
- Cancer Research and Treatments
- Computational Drug Discovery Methods
- Cannabis and Cannabinoid Research
- Immune Cell Function and Interaction
- Nausea and vomiting management
- Ethics in Clinical Research
Calvary Mater Newcastle Hospital
2016-2025
University of Newcastle Australia
2016-2024
Centre for Cancer Biology
2024
Hunter Medical Research Institute
2014-2023
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
2023
The University of Sydney
2021
UNSW Sydney
2020
New South Wales Department of Health
2018-2019
National Health and Medical Research Council
2019
Ontario Institute for Cancer Research
2010-2016
Abstract Background Approximately 50% of newly diagnosed glioblastomas (GBMs) harbor epidermal growth factor receptor gene amplification (EGFR-amp). Preclinical and early-phase clinical data suggested efficacy depatuxizumab mafodotin (depatux-m), an antibody–drug conjugate comprised a monoclonal antibody that binds activated EGFR (overexpressed wild-type EGFRvIII-mutant) linked to microtubule-inhibitor toxin in EGFR-amp GBMs. Methods In this phase III trial, adults with centrally confirmed,...
Hypochlorous acid is the most powerful oxidant generated by neutrophils and likely to contribute damage mediated these inflammatory cells. The haem enzyme myeloperoxidase catalyses its production from hydrogen peroxide chloride. 4-Aminobenzoic hydrazide (ABAH) a potent inhibitor of hypochlorous production. In this investigation we show that, in presence peroxide, ABAH irreversibly inactivates myeloperoxidase. was oxidized myeloperoxidase, kinetic analysis inactivation conformed that for...
The cancer stem cell (CSC) model proposes that tumors have a hierarchical organization in which only some cells indefinitely self-renew and thereby sustain tumor growth. In addition, the CSC requires tumor-initiating (TICs) be prospectively isolatable on basis of their phenotype. Previous studies suggested serous ovarian (SOC) conforms to model, but these used arguably nonfidelitous immortalized lines, cultured primary cells, or passaged xenografts as source cells. We developed robust assay...
Abstract FoxP3 is a member of the forkhead family transcription factors critically involved in development and function CD25+ regulatory T cells (Treg). Until recently, expression was thought to be restricted T-cell lineage. However, using immunohistochemistry flow cytometric analysis human melanoma tissue, we detected not only tumor infiltrating Treg but also themselves. widely expressed by established cell lines (as determined cytometry, PCR, Western blot), as well derived from other solid...
Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in broader, pretreated population, including patients ineligible the pivotal IMvigor211 phase 3 trial of atezolizumab. To determine safety and efficacy an international real-world setting. Between November 2016 March 2018 (median follow-up 12.7 mo), 1004 with advanced or metastatic nonurothelial urinary tract carcinoma who experienced...
Abstract Purpose: Successful implementation of genomic testing in clinical practice is critical for identification men with metastatic castration-resistant prostate cancer (mCRPC) eligible olaparib and future molecularly targeted therapies. Patients Methods: An investigational trial assay, based on the FoundationOneCDx tissue test, was used to prospectively identify patients qualifying homologous recombination repair gene alterations phase III PROfound study. Evaluation next-generation...
5000 Background: We previously reported that in men with mCRPC progressing after docetaxel randomly assigned LuPSMA vs. cabazitaxel (Lancet 2021), those has significant improvements PSA response rate (66% 37%), RECIST (49% 24%), progression-free survival (HR 0.63), less G3-4 toxicities (33% 53%) and better patient-reported outcomes. now report the secondary endpoint of overall (OS) mature follow-up, for trial participants, also initially excluded because low PSMA-expression or discordant...
177LuPSMA is an effective treatment in metastatic castrate-resistant prostate cancer with trials adopting a standardised dose interval. Adjusting intervals utilising early response biomarkers may improve patient outcomes.This study evaluated progression-free survival (PFS) and overall (OS) based on interval adjustment 24-h SPECT/CT (177Lu-SPECT) prostate-specific antigen (PSA) response.Retrospective analysis of clinical 177Lu-PSMA-I&T programme.In all, 125 men were treated 6-weekly...
Myeloperoxidase is the most abundant protein in neutrophils and catalyses conversion of H2O2 chloride into HOCl. To help clarify role this enzyme bacterial killing inflammation, a specific potent inhibitor needs to be identified. We have studied series benzoic acid hydrazides found that general they inhibit peroxidation activity myeloperoxidase with an IC50 value less than 10 microM. The values derivatives substituents containing oxygen or nitrogen were related their Hammett substituent...
Cell surface proteins have a wide range of biological functions, and are often used as lineage-specific markers. Antibodies that recognize cell antigens widely research tools, diagnostic markers, even therapeutic agents. The ability to obtain broad protein profiles would thus be great value in fields. There however currently few available methods for high-throughput analysis large numbers proteins. We describe here flow cytometry (HT-FC) platform rapid 363 antigens. Here we demonstrate HT-FC...
5500 Background: LuPSMA is a radiolabeled small molecule that delivers therapeutic β-radiation to PSMA-expressing tumors. Encouraging efficacy and safety has been shown in non-randomized studies of mCRPC. TheraP randomized phase II trial comparing vs cabazitaxel men with mCRPC progressing after docetaxel. Methods: Men mCRPC, imaging 68 Ga-PSMA-11 18 F-FDG PET/CT confirmed high PSMA-expression no sites FDG-positive/PSMA-negative disease, were randomly assigned (1:1) (6-8GBq q6weeks up 6...
PURPOSE The aim of this randomized, placebo-controlled, two-stage, phase II/III trial was to determine the efficacy an oral cannabis extract in adults with refractory nausea and/or vomiting during moderately or highly emetogenic, intravenous chemotherapy despite guideline-consistent antiemetic prophylaxis. Here, we report results prespecified combined analysis including initial II and subsequent III components. PATIENTS AND METHODS Study treatment consisted capsules containing either...
Loss-of-function mutations in the gene coding for perforin (PRF1) markedly reduce ability of cytotoxic T lymphocytes and natural killer cells to kill target cells, causing immunosuppression impairing immune regulation. In humans, nearly half cases type 2 familial hemophagocytic lymphohistiocytosis are due bi-allelic PRF1 mutations. The partial inactivation that promote protein misfolding or common hypomorphic allele A91V substitution have been associated with lymphoid malignancies childhood...